Serum amyloid alpha in parapneumonic effusions

Diagnostic value of soluble biomarkers for parapneumonic pleural effusion

Parapneumonic pleural effusion (PPE) is a common complication in patients with pneumonia. Timely and accurate diagnosis of PPE is of great value for its management. Measurement of biomarkers in circulating and pleural fluid have the advantages of easy accessibility, short turn-around time, objectiveness and low cost and thus have utility for PPE diagnosis and stratification. To date, many biomarkers have been reported to be of value for the management of PPE. Here, we review the values of pleural fluid and circulating biomarkers for the diagnosis and stratification PPE. The biomarkers discussed are C-reactive protein, procalcitonin, presepsin, soluble triggering receptor expressed on myeloid cells 1, lipopolysaccharide-binding protein, inflammatory markers, serum amyloid A, soluble urokinase plasminogen activator receptor, matrix metalloproteinases, pentraxin-3 and cell-free DNA. We found that none of the available biomarkers has adequate performance for diagnosing and stratifying PPE. Therefore, further work is needed to identify and validate novel biomarkers, and their combinations, for the management of PPE.

Pleural fluid biochemical analysis: the past, present and future

Identifying the cause of pleural effusion is challenging for pulmonologists. Imaging, biopsy, microbiology and biochemical analyses are routinely used for diagnosing pleural effusion. Among these diagnostic tools, biochemical analyses are promising because they have the advantages of low cost, minimal invasiveness, observer independence and short turn-around time. Here, we reviewed the past, present and future of pleural fluid biochemical analysis. We reviewed the history of Light’s criteria and its modifications and the current status of biomarkers for heart failure, malignant pleural effusion, tuberculosis pleural effusion and parapneumonic pleural effusion. In addition, we anticipate the future of pleural fluid biochemical analysis, including the utility of machine learning, molecular diagnosis and high-throughput technologies. Clinical Chemistry and Laboratory Medicine (CCLM) should address the topic of pleural fluid biochemical analysis in the future to promote specific knowledge in the laboratory professional community.

Reactive oxygen species measure for rapid detection of infection in fluids

BACKGROUND

Early detection of infection is critical to rapidly starting effective treatment. Diagnosis can be difficult, particularly in the intensive care unit (ICU) population. Because the presence of polymorphonuclear neutrophils in tissues is the hallmark of inflammatory processes, the objective of this proof of concept study was to determine whether the measurement of reactive oxygen species (ROS) could be an efficient diagnostic tool to rapidly diagnose infections in peritoneal, pleural and bronchoalveolar lavage (BAL) fluids in ICU patients.

METHODS

We prospectively included all patients hospitalized in the 21-bed surgical ICU of a teaching hospital from June 2010 to February 2014 who presented with systemic inflammatory response syndrome with suspicion of a peritoneal or pleural fluid or pulmonary infection needing a BAL. Instantaneous basal ROS production was measured in fluids and after phorbol 12-myristate 13-acetate (PMA) stimulation. We compared patients with infected fluids to those with non-infected fluids.

RESULTS

The overall ICU mortality rate was 34 %. A majority of patients were sampled following a delay of 5 days (2-12) after ICU admission, with most receiving antibiotics at the time of fluid sampling (71 %). Fluids were infected in 21/65 samples: 6/17 peritoneal fluids, 8/28 pleural fluids and 7/20 BALs. ROS production was significantly higher in the infected than in the non-infected group at baseline and after PMA stimulation in the peritoneal and pleural fluids but not in BAL.

CONCLUSION

Assessing instantaneous ROS production appears as a fast and reliable diagnostic method for detecting peritoneal and pleural fluid infection.

Prognostic value of C-reactive protein in parapneumonic effusions

BACKGROUND AND OBJECTIVE

Parapneumonic effusions (PPE) that require drainage are referred to as complicated parapneumonic effusions (CPPE). Following resolution of these effusions, residual pleural thickening (RPT) may persist. We hypothesize that the concentrations of CRP in pleural fluid (CRP(pf)) and serum (CRP(ser)) can be used to identify CPPE and to predict RPT.

METHODS

All patients with non-purulent PPE, who were admitted to two tertiary hospitals during a 30-month period, were enrolled in the study. Baseline CRP(pf) and CRP(ser) levels were compared between patients with complicated or uncomplicated PPE, as well as between patients with or without RPT of >10 mm, 6 months after discharge from hospital. Cut-off values for identification of CPPE and prediction of RPT were determined by receiver operating characteristic curve analysis. Logistic regression analysis was performed to assess the association between CRP levels and RPT.

RESULTS

Fifty-four patients were included in the study. Patients with CPPE (n = 23) had significantly higher levels of both CRP(pf) and CRP(ser) than those with uncomplicated PPE. For identification of CPPE, a CRP(pf) level >78.5 mg/L and a CRP(ser) level >83 mg/L gave 84% and 47% sensitivity, with 65% and 87% specificity, respectively. Classical criteria (pleural fluid pH <7.20, LDH >1000 IU/L, glucose <600 mg/L) were superior for this purpose. A combination of classical biomarkers with CRP levels using an 'AND' or 'OR' rule improved the positive and negative predictive values, respectively. CRP(ser) was an independent predictor for development of RPT (adjusted OR 1.18). A CRP(ser) level >150 mg/L had 91% specificity and 61% sensitivity for prediction of RPT.

CONCLUSIONS

This study demonstrated the value of CRP(ser) for prediction of RPT in patients with PPE. Moreover, when used in combination with classical biomarkers, CRP levels may be a useful adjunct for decision-making in relation to treatment of patients with non-purulent PPE.